Effects of JM216 on Ovarian Cancer Cells
Author Information
Author(s): O’Neill C F, Koberle B, Masters J R W, Kelland L R
Primary Institution: Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research
Hypothesis
How does the oral platinum drug JM216 affect ovarian carcinoma cell lines that are sensitive and resistant to cisplatin?
Conclusion
JM216 induces apoptosis in ovarian cancer cells and shows comparable cytotoxicity to cisplatin, with differences in gene-specific repair capabilities.
Supporting Evidence
- JM216 showed comparable cytotoxicity to cisplatin in three ovarian cancer cell lines.
- Resistant cell lines were able to repair JM216 induced DNA damage more effectively than sensitive ones.
- JM216 induced apoptosis in all tested cell lines after a short incubation period.
Takeaway
JM216 is a new cancer drug that works similarly to cisplatin but can cause cancer cells to die in a different way.
Methodology
The study involved testing JM216 on three ovarian cancer cell lines and measuring platinum accumulation, DNA binding, and apoptosis induction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website